These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 7766610)

  • 1. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents.
    Sackett DL
    Biochemistry; 1995 May; 34(21):7010-9. PubMed ID: 7766610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
    Mooberry SL; Taoka CR; Busquets L
    Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S; Bhattacharyya B
    Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging of tubulin at neutral pH: the destabilizing effect of vinca alkaloids.
    Prakash V; Timasheff SN
    Arch Biochem Biophys; 1992 May; 295(1):137-45. PubMed ID: 1575510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.
    Hamel E
    Pharmacol Ther; 1992; 55(1):31-51. PubMed ID: 1287674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
    Chaudhuri AR; Seetharamalu P; Schwarz PM; Hausheer FH; Ludueña RF
    J Mol Biol; 2000 Nov; 303(5):679-92. PubMed ID: 11061968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antimitotic agents on tubulin-nucleotide interactions.
    Correia JJ
    Pharmacol Ther; 1991 Nov; 52(2):127-47. PubMed ID: 1818332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
    Jordan A; Hadfield JA; Lawrence NJ; McGown AT
    Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin.
    Sackett DL; Varma JK
    Biochemistry; 1993 Dec; 32(49):13560-5. PubMed ID: 8257691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
    Owellen RJ; Hartke CA; Dickerson RM; Hains FO
    Cancer Res; 1976 Apr; 36(4):1499-502. PubMed ID: 1260766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
    Houghton PJ; Houghton JA; Bowman LC; Hazelton BJ
    Anticancer Drug Des; 1987 Oct; 2(2):165-79. PubMed ID: 3329524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
    Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
    J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tubulin polymerization by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin 10.
    Edler MC; Fernandez AM; Lassota P; Ireland CM; Barrows LR
    Biochem Pharmacol; 2002 Feb; 63(4):707-15. PubMed ID: 11992639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The binding of vinca domain agents to tubulin: structural and biochemical studies.
    Cormier A; Knossow M; Wang C; Gigant B
    Methods Cell Biol; 2010; 95():373-90. PubMed ID: 20466145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Instability of pleomorphic tubulin paracrystals artificially induced by Vinca alkaloids in tissue-cultured cells.
    Takanari H; Yosida T; Morita J; Izutsu K; Ito T
    Biol Cell; 1990; 70(1-2):83-90. PubMed ID: 2085693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhizoxin binding to tubulin at the maytansine-binding site.
    Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y
    Biochim Biophys Acta; 1987 Dec; 926(3):215-23. PubMed ID: 3120782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.